RANCHO CUCAMONGA – October 29, 2026 -- Amphastar Pharmaceuticals (NASDAQ: AMPH) will publish results for the third quarter ended September 30, 2026, after the market closes on Thursday, November 5, 2026.
Amphastar schedules a 2:00 p.m. Pacific call to discuss the quarter
Management will hold a conference call at 2:00 p.m. Pacific Time on the same day. Participants can dial 877-407-0989 toll-free or 201-389-0921 from outside the United States, ten minutes before the start. A webcast of the call will run on the Investors page of the company website, and a replay will be posted within 24 hours of the call's end.
BAQSIMI sales sustainability is a named risk factor
In its forward-looking statements, Amphastar states there is no guarantee that its sales strategies will succeed or that it will continue to see significant sales of BAQSIMI. The company's trademarked portfolio also includes Primatene MIST, Amphadase and Cortrosyn.
Most of Amphastar's finished products are contracted and distributed through group purchasing organizations, drug wholesalers and drug retailers. The company also sells active pharmaceutical ingredient (API) products.
Prior 2026 filings frame the risk disclosures
Amphastar points investors to its 10-K for fiscal 2025, filed February 26, 2026, and its 10-Qs filed May 7, 2026 (Q1) and August 6, 2026 (Q2), for factors that could cause actual results to differ materially from expectations. The company says its statements cover timing of FDA filings or approvals, product launches and pipeline progress.